Начало・Списък с акции・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Отворен

СекторЗдравеопазване

258.57 9.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

231.82

Максимум

263.86

Ключови измерители
By Trading Economics
Приходи	262M -15M
Продажби	1.6M 996M
EPS	2.06
Марж на печалбата	-1.486
Служители	18,300
EBITDA	-135M 64M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-1.67% downside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.8B 11B
Предишно отваряне	249.11
Предишно затваряне	258.57

Настроения в новините

By Acuity

10%

90%

14 / 340 Класиране в Healthcare

Charles River Laboratories International Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:16 ч. UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

3.08.2026 г., 22:06 ч. UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

31.07.2026 г., 19:46 ч. UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30.07.2026 г., 23:01 ч. UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29.07.2026 г., 19:18 ч. UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

28.07.2026 г., 18:02 ч. UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

27.07.2026 г., 17:36 ч. UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

23.07.2026 г., 00:01 ч. UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

22.07.2026 г., 22:01 ч. UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

21.07.2026 г., 21:01 ч. UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20.07.2026 г., 21:01 ч. UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Сравнение с други в отрасъла

Ценова промяна

Charles River Laboratories International Inc Прогноза

Ценова цел

By TipRanks

-1.67% надолу

12-месечна прогноза

Среден 230.2 USD -1.67%

Висок 265 USD

Нисък 213 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Charles River Laboratories International Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Charles River Laboratories International Inc през последните 3 месеца.

Настроение

By Acuity

14 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.